Premaitha Share Discussion Threads

[timojelly] 21/12/2016 08:53

Glad you have all sold up (if you ever had any), good luck with your future investments, TA TA.

[woodcutter] 21/12/2016 08:52

classic investor cognitive dissonance at play here. The chart says it all really

wc

[waterloo01] 21/12/2016 08:51

or VIY oh, been there.

[deanroberthunt] 21/12/2016 08:47

should change the name to Jam & Confetti R US

[tsmith2] 21/12/2016 08:33

more jam more jam confetti

[deanroberthunt] 21/12/2016 08:06

running the numbers revenue would to be near £30-40m to make any money....fat chance this side of terraforming Mars

[timojelly] 21/12/2016 08:06

OK then, I believe you more than the company.

[2vdm] 21/12/2016 08:05

I'm out but good luck to all. Expenditure too high to be sustainable. I hope the strategic acquisition works. it makes sense, but as ever cash flow is king. I'll keep watching.

[timojelly] 21/12/2016 08:00

The European issue will be concluded 2017 but that will no be do or die for Premaitha, hence the Far East move.

[timojelly] 21/12/2016 07:58

Carry on reading... 'Acquisition of Yourgene - a significant NIPT provider in Asia (based in Taiwan) - Expanded market access in Asia - Cross-selling opportunities - Expanded content both within and beyond NIPT - Combined strategic drive into China - Litigation de-risked due to non-registration of Illumina controlled patents within Taiwan -- General Meeting in relation to the Acquisition and a proposed share sub-division'Note...... 'combined strategic drive into China'......

[pugg1ey] 21/12/2016 07:56

'Advanced talks' doesn't pay the bills, cash from Genoma does.

I used to be an enthusiastic holder here, but I fear Illumina have done their job with the 'litigation' effort. Genoma is just another kick in the privates.

[timojelly] 21/12/2016 07:54

Carry on reading.. 'o Advanced talks with major European laboratory chain'To counter Genoma?

[woodcutter] 21/12/2016 07:38

Equity cash call coming. As i noted in my post 4186 absolutely no commercial acumen whatsoever, a bunch of medical academics using shareholders money as their plaything.

I note the shares have been restructured as the share price is below the 10p par value. Now sub divided with a new par value of 0.1p. If they keep spending at this rate then I can see the share price falling below that par value.

aimho woody

post note: there is no cash flow, receivables too high and cash generated from operations is worse than the loss at P&L level. They're holding back paying their creditors as they are not getting paid quickly enough by their debtors.

[pugg1ey] 21/12/2016 07:36

that is possibly for the future. Genoma is the present, and vital to Premaitha's cash flow.

[hurricane.] 21/12/2016 07:33

Massively de-risked with the acquisition. And access into the Chinese market

[pugg1ey] 21/12/2016 07:28

But a disaster regarding the situation at Genoma

[hurricane.] 21/12/2016 07:24

Excellent acquisition. That explains the recent strength then

[deanroberthunt] 21/12/2016 07:21

I don't believe em......

[timojelly] 21/12/2016 07:18

Carry on reading please'OutlookNow that the Company is starting to achieve revenue scale it is important we operate on a sustainable cost base, and we intend to achieve cashflow breakeven in the second half of next year. A sizeable proportion of our development costs are nearing completion and with the addition of the Yourgene team we see further growth opportunities within Asia. There has been a significant increase recently in the awareness of the benefits of NIPT, with the UK's NHS to offer the test as standard to high risk women from 2018. We now have a significant geographic presence and partners in place to ensure the IONA(R) test forms a fundamental and key role in the uptake of NIPT testing internationally and we look forward to the future with confidence.''cash flow breakeven '.......

[hjb1] 21/12/2016 01:10

Don't then!! thanks anyway.

[woodcutter] 20/12/2016 17:56

Had a look at these this morning thinking they may be about to turn based on the news flow and chart, litigation excluded of course.

Then i crunched some numbers;
revenue £2.5m roughly
gross profit £800k roughly
gross margin around 30% it's slightly less than this
number of tests 17000
admin costs excluding legals £6.6m roughly

So how many tests to support break even
cost of per test around £147 (2.5m/17000)It's probably less than this as some revenue was for equipment sales just over £372K.
Assuming admin costs stand still which they won't then to break even they've got to sell around 170000 tests, a ten fold increase.

this is based on:
revenue £24m (170k @ £140)
gross margin 30%
gross profit £7.2m
admin costs £7.2m inlcd share based payments and finance costs etc.

At some point they probably be doing way more than 170k of tests but in the short term it looks to me like they'll need to get tighter control of costs.

other negatives the legal case and it's costs and distraction, the costs of thermo fisher loans (these guys don't look like mugs) and worse the shed load of dilutive warrants too at over 37m that's equivalent to over 16% of the current shares in issue. I figure this is only going one way.............themo fishers

happy to have my synopsis questioned in case i've misinterpreted something.

conclusion.................it's uninvestable at the present

woody

post note: 9 directors troughing over £850K between them on revenue of £2.5m...............nice if you can get it. It's looks very much like it's a gravy train with little concept of commercial reality. The cash will soon be burned at this rate.